SNYNF - Regeneron's Latest Approval And Other News: The Good Bad And Ugly Of Biopharma
Regeneron Receives FDA Nod for Dupixent
Regeneron Pharmaceuticals (REGN) reported that the FDA has given its approval for a 300 mg single-dose prefilled pen formulation of Dupixent. The drug is now authorized for treating certain patients at least 12 years old with atopic dermatitis, asthma or chronic rhinosinusitis with nasal polyposis. The company is collaborating with Sanofi (SNY) for developing this treatment.
Regeneron stated that the pen is approved for at-home use and will offer more convenient option for patients for administering the drug. George D. Yancopoulos, M.D., Ph.D., Co-founder, President